Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (FY)Dec 31, 2021 | (Q9)Sep 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 3.09%23.16B | 24.33%11.7B | 39.05%22.46B | --9.41B | 7.44%16.16B | 51.87%15.04B | 31.31%9.66B | 21.56%9.9B | --7.36B | 47.66%8.15B |
| Operating income | 3.09%23.16B | 24.33%11.7B | 39.05%22.46B | 9.41B | 7.44%16.16B | 51.87%15.04B | 31.31%9.66B | 21.56%9.9B | 7.36B | 47.66%8.15B |
| Cost of sales | ---- | -17.29%-9.67B | ---- | ---8.24B | -23.65%-16.04B | -41.93%-12.97B | -40.02%-9.06B | -83.43%-9.14B | ---6.47B | -25.12%-4.98B |
| Operating expenses | -15.52%-19.98B | -17.29%-9.67B | -7.84%-17.29B | -8.24B | -23.65%-16.04B | -41.93%-12.97B | -40.02%-9.06B | -83.43%-9.14B | -6.47B | -25.12%-4.98B |
| Gross profit | -38.46%3.18B | 74.04%2.03B | 4,221.42%5.17B | 1.17B | -94.21%119.67M | 170.67%2.07B | -31.86%607.9M | -75.85%764.1M | 892.12M | 106.15%3.16B |
| Selling expenses | -1.90%-103.38M | 4.30%-45.4M | 7.68%-101.45M | ---47.44M | -36.90%-109.9M | -10.54%-80.28M | -2.77%-52.54M | -3.61%-72.62M | ---51.12M | -30.68%-70.09M |
| Administrative expenses | -3.11%-1.31B | -15.06%-804.66M | 1.52%-1.27B | ---699.35M | -21.73%-1.29B | -18.95%-1.06B | -11.88%-736.1M | -27.04%-889.63M | ---657.95M | -75.32%-700.29M |
| Research and development expenses | -0.68%-277.22M | ---- | ---275.33M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Profit from asset sales | 23.57%533.48K | ---- | --431.72K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Revaluation surplus | -611.11%-47.09M | -92.32%112.76M | 99.07%-6.62M | --1.47B | -332.56%-708.83M | 111.07%304.8M | 134.70%1.26B | -312.51%-2.75B | ---3.62B | 20.21%1.3B |
| -Changes in the fair value of other assets | -611.11%-47.09M | -92.32%112.76M | 99.07%-6.62M | --1.47B | -332.56%-708.83M | 111.07%304.8M | 134.70%1.26B | -312.51%-2.75B | ---3.62B | 20.21%1.3B |
| Impairment and provision | -104.41%-29.34M | 139.88%2.53M | 16.98%-14.35M | ---6.35M | -29.67%-17.29M | -125.32%-13.33M | -91.31%-5.02M | -164.15%-5.92M | ---2.62M | 49.26%-2.24M |
| -Other impairment is provision | -104.41%-29.34M | 139.88%2.53M | 16.98%-14.35M | ---6.35M | -29.67%-17.29M | -125.32%-13.33M | -91.31%-5.02M | -164.15%-5.92M | ---2.62M | 49.26%-2.24M |
| Special items of operating profit | 26.51%293.76M | 67.49%223.98M | -48.89%232.2M | --133.73M | 309.67%454.3M | 8.28%110.89M | 136.28%106.07M | 31.37%102.41M | --44.89M | 257.02%77.96M |
| Operating profit | -54.86%1.67B | -24.66%1.52B | 339.10%3.71B | 2.02B | -216.37%-1.55B | 146.66%1.33B | 134.66%1.18B | -175.84%-2.86B | -3.4B | 72.94%3.76B |
| Financing cost | ---- | 32.23%-151.23M | ---- | ---223.16M | -8.94%-441.52M | -29.79%-405.27M | -36.75%-307.81M | -100.68%-312.24M | ---225.1M | -83.81%-155.59M |
| Share of profits of associates | ---- | -1,573.93%-6.68M | ---- | ---399K | 99.41%-96K | -400.83%-16.38M | -622.07%-15.87M | -842.65%-3.27M | ---2.2M | ---347K |
| Special items of earning before tax | 29.78%-45.98M | ---- | ---65.48M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Earning before tax | -56.49%1.42B | -24.07%1.36B | 264.13%3.27B | 1.79B | -318.77%-1.99B | 128.71%910.44M | 123.55%852.97M | -187.85%-3.17B | -3.62B | 72.49%3.61B |
| Tax | ---- | 98.50%-5K | ---- | ---333K | 47.79%-355K | 65.76%-680K | 68.19%-849K | -198.20%-1.99M | ---2.67M | -31.36%-666K |
| After-tax profit from continuing operations | -56.51%1.42B | -24.05%1.36B | 264.09%3.27B | 1.79B | -318.97%-1.99B | 128.67%909.76M | 123.51%852.12M | -187.93%-3.17B | -3.63B | 72.50%3.61B |
| Earning after tax | -56.51%1.42B | -24.05%1.36B | 264.09%3.27B | 1.79B | -318.97%-1.99B | 128.67%909.76M | 123.51%852.12M | -187.93%-3.17B | -3.63B | 72.50%3.61B |
| Minority profit | -110.67%-11.64M | 172.71%67.98M | 150.25%109.04M | --24.93M | -161.11%-217.01M | 52.60%-83.11M | 50.10%-75.69M | -245.91%-175.36M | ---151.68M | 34.62%120.18M |
| Profit attributable to shareholders | -54.64%1.43B | -26.83%1.29B | 278.01%3.16B | 1.77B | -278.79%-1.78B | 133.13%992.87M | 126.71%927.81M | -185.93%-3B | -3.47B | 74.19%3.49B |
| Basic earnings per share | -54.61%3.69 | -26.87%3.32 | 266.60%8.13 | 4.54 | -278.10%-4.88 | 132.93%2.74 | 126.53%2.56 | -185.25%-8.32 | -9.65 | 58.18%9.76 |
| Diluted earnings per share | -54.61%3.69 | -26.87%3.32 | 266.60%8.13 | 4.54 | -278.10%-4.88 | 132.93%2.74 | 126.53%2.56 | -185.25%-8.32 | -9.65 | 58.18%9.76 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | KPMG | -- | KPMG | KPMG | -- | KPMG | -- | KPMG |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.